Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Vaping 1Tobacco Use Disorder 1Stomach Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Granulosa Cell Tumor 1Endometrial Neoplasms 1Abiraterone Acetate 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × BID protein, human × Clear all
NCT04355039 2020-08-19

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Medical College of Wisconsin

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡